about
Bivalirudin in percutaneous coronary interventionDirect thrombin inhibitors: pharmacology and clinical relevance.Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudinBivalirudin: a review of the pharmacology and clinical application.Direct thrombin inhibitors.Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised cDirect thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.Anticoagulation in coronary intervention.Bivalirudin in Patients Undergoing PCI: State of Art and Future Perspectives.Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control.Use of prothrombin complex concentrate containing heparin for emergency reversal of bivalirudin anticoagulation: a word of caution.Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiologyA GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics
P2860
Q28219409-2C7802DD-9D74-47BD-B9CF-D5419848EB15Q33366516-064C1122-6065-417A-81C2-EDCFC0A2B9A0Q33373700-71A61E9B-08F7-4BE3-BCE6-2C88C5701BFBQ33381356-7C54BBD8-BF5D-47E1-A45C-0A2F4F00C1AAQ33392973-49C09ABD-3483-4A13-B8A9-84A3DEE72A94Q33393692-DBA0A764-E0A3-4201-96C2-58C86E80DFDFQ33400101-709A0554-60C8-4091-B932-6EA303AFE9A9Q34305843-A500DF3A-A16D-4F85-9B40-B0A7BD66AF07Q36909343-E10E5196-D1AA-4A4A-9ACE-ACD9C52B315DQ38647203-5BE59BDC-BE9A-4A8F-9931-53FD5A6A14F8Q38762278-A4154B82-FBA7-495C-BA99-F394AF808438Q38850355-BD9C2069-D8BD-429B-9E1F-CD3FE017F724Q39885450-3BEE52BF-DAB1-460E-85B6-2822D308A58CQ47238848-D69381FA-CE55-4CDF-A1BA-F5B52EC56FBFQ57716709-8E23F229-F18F-4DC3-B764-2B6E494E6772Q58294605-1D1543D6-7D28-413B-90E0-4FE8A3A68150
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical pharmacology of bivalirudin.
@ast
Clinical pharmacology of bivalirudin.
@en
type
label
Clinical pharmacology of bivalirudin.
@ast
Clinical pharmacology of bivalirudin.
@en
prefLabel
Clinical pharmacology of bivalirudin.
@ast
Clinical pharmacology of bivalirudin.
@en
P2860
P1433
P1476
Clinical pharmacology of bivalirudin.
@en
P2093
Michael D Reed
P2860
P304
P356
10.1592/PHCO.22.10.105S.33616
P407
P433
P577
2002-06-01T00:00:00Z